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Introduction 
“Bile acid: An acid made by the liver that works with bile to break down fats”  
Definition by Webster’s New world, medical dictionary 
 
Great progress has been made in understanding the physiological role of bile acids 
during the last years. Bile acids first regarded only as molecules synthesized by 
cholesterol serving to emulsify lipids and fat soluble vitamins in the intestine are now 
known to have multiple functions. A major breakthrough elucidating the function of bile 
acids came with the discovery that bile acids are endogenous ligands of the farnesoid X 
receptor (FXR) and exert signaling activities to regulate gene expression in a variety of 
tissues including liver and intestine.  
FXR is a member of the nuclear receptor superfamily of ligand induced transcription 
factors and serves as the master regulator of bile acid homeostatis, controlling bile acid 
synthesis and transport. As bile acids are detergents and potentially toxic to cells their 
levels and their de novo sxnthesis need to be tightly regulated. Synthesis of bile acids is 
a major consumer of cholesterol. The body synthesizes about 800 mg of cholesterol per 
day and about half of that is used for bile acid synthesis. In total about 20-30 grams of 
bile acids are secreted into the intestine daily; about 90% of excreted bile acids are 
reabsorbed by active transport and recycled. This is referred to as the enterohepatic 
circulation and many transport proteins are involved in it. Disruption of bile acid transport 
can cause various diseases including bile acid malabsorption and cholestasis. Therefore, 
the efflux of bile acids need to be tightly regulated. 
Today it is well established that activation of FXR by bile acids induces a transcriptional 
response to coordinately regulate bile acid, cholesterol, triglyceride and glucose 
metabolism. Bile acids together with FXR protect the intestinal mucosa from bacterial 
overgrowth and inflammatory insults and are also known to function in normal liver 
regeneration and to play a protective role in liver carcinogenesis. In addition bile acids 
can also influence gene expression via FXR-independent pathways. 
This ‘Habilitationsschrift’ describes ongoing work towards the function and transport of 
bile acids. It describes: (I) How bile acids act in complex networks and have an impact 
on various metabolic pathways. (II) How transport of bile acids is regulated in liver and 
the intestine. 
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Own research 
I. Bile acids as global regulators 
Bile acids have multiple functions in the body and more and more new roles are 
discovered. First shown to be an important component in the regulation of their own 
metabolism, it is now well established that bile acids also act as global regulators and 
participate in many other networks and pathways (Fig. 1). The following publications 
provide some examples of bile acids acting as global regulators.  
 
Fig. 1: Bile acids activate the nuclear farnesoid 
receptor (FXR). Bile acid-activated FXR has 
pleiotropic functions and plays a role in various 
pathways.  
 
 
Bile acids and detoxification 
Jung D, Mangelsdorf DM, Meyer UA: FXR activates PXR. JBC, 2006 Jul 14;281(28):19081-91  
Bile acids in high concentrations are toxic and therefore tightly regulated. Two systems, bile acid 
synthesis and catabolism account for this. Bile acid synthesis is governed transcriptionally by the 
farnesoid X receptor (FXR). Bile acid catabolism involves several enzymes regulated by the 
pregnane X receptor (PXR). PXR is an essential component of the body's detoxification system 
PXR and is activated by a broad spectrum of xenobiotics and endobiotics, including bile acids 
and their precursors. As PXR is an important component of bile acid homeostasis, a direct 
connection between PXR and bile acid-activated FXR can be assumed. 
This paper established a mouse model using wildtype and FXR knock-out mice to prove this 
concept. Both feeding mice with the bile acid, cholic acid, or with a synthetic FXR agonist, 
resulted in a robust PXR induction. This effect was abolished in FXR knockout mice, 
demonstrating that PXR expression was indeed activated by bile acids via the FXR pathway. In 
addition prolonged bile acid treatment in wildtype mice was shown to increase PXR target genes 
such as cytochrome P450 enzymes, responsible for bile acid breakdown. The same paper also 
described the molecular mechanism. Within the PXR gene a region containing four bile acid 
response elements was identified and characterized.  
This paper demonstrated clearly that there is crosstalk between PXR and FXR. Bile acids activate 
FXR, which blocks synthesis of bile acids. Bile acid-activated FXR also induces the expression of 
PXR and also activates PXR, promoting breakdown of bile acids (Fig. 2). The combination of the 
two mechanisms lead to an efficient protection of the liver against bile acid induced toxicity. 
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Fig. 2: Bile acids activate FXR. FXR induces the 
expression of PXR and leads to the inhibition of 
bile acid synthesis. PXR is activated by bile 
acids and promotes the breakdown of bile acids. 
 
 
 
Bile acids and heme synthesis: 
Peyer A-K, Jung D, Beer M, Gnerre C, Zavolan M, Meyer UA: Heme synthesis in Human 
Liver is regulated by Bile Acids via the Farnesoid X Receptor. Hepatology, 2007, Dec, 46 
(6):1960-70 
Synthesis of heme is indispensable for life and takes place in every cell of the body except 
mature erythrocytes. Heme is synthesized in bone marrow for the production of hemoglobin and 
in liver, where it is incorporated into various heme proteins (e.g. cytochromes P450, catalases, 
peroxidases and respiratory cytochromes). Because either excess or deficiency of heme is 
detrimental to the cell, heme synthesis needs to be tightly controlled. In nonerythroid cells, the 
rate of heme synthesis is controlled at its first enzymatic step. Accordingly the first enzyme of the 
synthesis pathway, δ-aminolevulinic acid synthase 1 (ALAS1), is highly regulated in different 
cellular contexts to ensure adequate levels of intracellular heme.  
Several lines of evidence suggested a connection between bile acid homeostasis and the 
regulation of hepatic heme synthesis. Bile acid precursors were shown to induce ALAS1 activity 
in chicken embryo hepatocytes. Moreover, in hepatobiliary diseases accompanied by cholestasis 
increased urinary excretion of porphyrinsis is a common feature. As bile acids are known to 
induce heme proteins, it was hypothesized that a similar mechanism may affect heme synthesis. 
This paper clearly showed that the human hepatic ALAS1 is a direct target of bile acids via the 
activated farnesoid X receptor (FXR). Experiments in primary human hepatocytes and in human 
liver slices demonstrated that ALAS1 expression and activity is increased upon exposure to the 
bile acid chenodeoxycholic acid (CDCA). In addition, a bile acid response element was identified 
in the 5´-flanking region of human ALAS1 and characterized.  
Therefore, this paper discovered a new role for bile acids and their nuclear receptor. Bile acids 
regulate the human ALAS1 gene and, consequently, hepatic porphyrin and heme synthesis. 
Hereditary partial defects of enzymes of heme synthesis lead to rare metabolic diseases known 
as porphyrias. Inducible, acute hepatic porphyrias are characterized by intermittent attacks of 
neuropsychiatric dysfunction precipitated by stimuli and are associated with increased hepatic 
ALAS1 activity. This data suggests that elevated endogenous bile acids may precipitate 
neuropsychiatric attacks in patients with acute hepatic porphyrias. 
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Bile acids and malabsorption: 
Jung D, Inagaki T, Gerard RD, Dawson PA, Kliewer SA, Mangelsdorf DJ Moschetta A: FXR 
agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid 
malabsorption. J. Lipid Research, 2007, Dec, 48 (12): 2693-700 
Bile acid malabsorption in patients leads to excessive fecal bile acid excretion and diarrhea. The 
apical sodium dependent bile acid transporter (ASBT), also called the ileal bile acid transporter, is 
the chief transport system responsible for reabsorbtion of bile acids in the intestine. Many 
inflammatory bowel disease (IBD) patients exhibit reduced expression of ASBT. Reduced ASBT 
expression results in an increased fecal bile salt excretion and experiments using orally ingested 
radiolabeled bile acids showed a decreased absorption. Treatment with glucocorticoids is 
beneficial and is related not only to suppression of inflammation and mucosal injury but also to 
increased bile acid absorption in the ileum through induction of ASBT. Of note, this is reported by: 
“Jung D, Fantin A, Scheurer U, Fried M., Kullak-Ublick GA.: Human Ileal Bile Acid Transporter 
Gene ASBT (SLC10A2) is transactivated by the Glucocorticoid Receptor. Gut 2004; 53 (1): 79-8.” 
referred as publication with high scientific impact in this habilitation, that will not discussed further.  
Malabsorption in patients is also characterized by a vicious cycle in which the feedback 
regulation of bile acid synthesis is interrupted, resulting in additional bile acid production. 
Feedback regulation of bile acid synthesis is under the control of an endocrine pathway, wherein 
the activation of the nuclear receptor FXR has an important role and, together with other FXR-
induced factors, leads to the repression of bile acid synthesis. Mice deficient in ASBT are not only 
unable to reabsorb bile acids in the intestine, they also have a disruption in the described 
pathway. ASBT knock-out mice are therefore a model to investigate mechanisms of 
malabsorption and potential therapies.  
This paper demonstrated that the bile acid mediated FXR pathway, disrupted in mice lacking the 
apical ileal bile acid transporter, can be restored. Treatment with an FXR agonist, e.g. specific 
synthetic bile acids was shown to reduce bile acid de novo synthesis, to decrease bile acid pool 
size and to reduce fecal bile acid excretion. This suggested that FXR agonists could be used 
therapeutically to interrupt the cycle of excessive bile acid production in patients with bile acid 
malabsorption. 
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II. Regulation of bile acid transport in the liver and intestine 
Bile acids are secreted into the intestine daily and about 90% of excreted bile acids are 
reabsorbed by active transport and recycled. This is referred to as the enterohepatic 
circulation and many transport proteins are involved in it (Fig. 3). The major driving force 
for bile acid excretion is the active vectorial transport of bile acids from blood into bile. 
Any disturbance in bile excretion leads to the accumulation of bile acids in hepatocytes 
and cholestatic liver damage. One defense mechanism against the accumulation of bile 
acids is provided due to the regulation of bile acid transport systems. The following 
publications give some examples how bile acid transport systems are regulated. 
 
Fig. 3: Bile acids are reabsorbed in the small intestine 
by the apical sodium dependent bile acid transporter 
(ASBT) and returned through the blood to the liver. Bile 
acid uptake in the liver is done by the Na-taurocholate 
cotransporting polypeptide (NTCP) and the organic 
anion transport peptide C (OATP-C). The bile acid 
export pump (BSEP) effluxes bile acid from the 
hepatocyte into bile, where they are reused. This is 
called the enterohepatic circulation.  
 
Regulation of bile acid uptake in the liver: 
Jung D, Hagenbuch B, Fried M, Meier PJ, Kullak-Ublick GA: Role of Liver-Enriched 
Transcription Factors and Nuclear Receptors in Regulating the Human, Mouse and Rat 
NTCP Gene. Am J Physiol Gastrointest Liver Physiol. 2004 May;286(5):G752-61. 
Accumulation of bile acids in the hepatocyte can lead to cholestatic liver damage found in 
conditions such as pregnancy, cholestasis, and sepsis. An early defense mechanism against the 
accumulation of bile acids is the downregulation of bile acid uptake systems. In mammalian liver, 
the Na-taurocholate cotransporting polypeptide (NTCP) accounts for 80% of conjugated bile acid 
uptake across the basolateral membrane of hepatocytes. NTCP is highly conserved between 
species and subject of an extensive regulation. Different models of cholestasis, such as bile acid 
feeding, bile duct ligation, or endotoxinemia showed downregulation of both NTCP mRNA and 
protein. Several mechanism regulating the expression of NTCP have been characterized in the 
rat, but little was known about mechanisms controlling the transcriptional regulation of the human 
or mouse NTCP gene and done in this paper.  
The initial characterization of the 5'- regulatory region of the human and mouse NTCP gene 
discovered a conserved region with a sequence identity of up to 80% among the human, mouse, 
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and rat. However, major differences in the distribution of potential transcription binding sites were 
revealed by sequence alignment. In vitro experiments showed that the liver-enriched 
transcriptions factors like hepatocyte nuclear factors (HNF1α, HNF3β and HNF4α) have an 
important but species-specific function in the regulation of the NTCP gene and that the 
transcriptional regulation of NTCP thus differs among human, mouse, and rat. 
The same paper showed also that the retinoic X and retinoic acid receptor dimer (RXR/RAR) 
suggested to be involved in the bile acid dependent downregulation is only bound and 
transactivated in the rat NTCP gene but not in human or mouse. As the NTCP gene does not 
possess a direct bile acid response element, it was suggested that bile acids regulate NTCP 
expression through indirect mechanisms. A mechanism for the supression of human NTCP gene 
by bile acids is described in the next chapter. 
 
Eloranta JJ, Jung D, Kullak-Ublick GA: The human Na+ Taurocholate Cotransporting Gene 
(NTCP, SLC10A1) is acitvated by the Glucocorticoid Receptor and its coactivator PGC-1 
and supressed by the small heterodimer partner SHP. Mol. Endocrinol. 2006 Jan; 20(1): 65-
79. 
Bile acids are detergents and therefore potentially toxic for cells. To protect the liver against 
accumulation of bile acids and cholestatic damage the expression of the main bile acid uptake 
system NTCP is reduced in response to increased intracellular bile acid concentrations. The 
exact molecular mechanism of decreased NTCP expression in cholestasis is unresolved. 
High bile salts concentrations activate a transcriptional repressor, called small heterodimer 
partner (SHP). SHP downregulates multiple genes involved in bile acid synthesis and transport. 
Several studies have shown that SHP interferes often with the transcriptional activity of other 
transcription factors. An example for this is the downregulation of the rat NTCP gene, here a 
positive acting transcription factors dimer composed of the nuclear receptor retinoic X and retinoic 
acid receptor (RXR/RAR) is repressed by interference with SHP, thus leading to decreased 
expression. The described does not account for the the regulation of the human NTCP gene as it 
does not possess a RXR/RAR binding site. 
This paper described the first potential mechanism mediating bile acid-dependent negative 
feedback regulation of the major bile acid uptake system NTCP in humans. It showed that the 
NTCP gene is a transcriptional target for the induction by glucocorticoids via their affinity to the 
glucocorticoid receptor (GR). For this activation a coactivator called peroxisome proliferator-
activated receptor- coactivator-1 (PGC1) was required. Bile acids as well as the bile acid-induced 
repressor SHP strongly antagonized the GR-dependent induction of the human NTCP gene.  
The new finding that next to the major uptake system in the intestine, ASBT, also the major bile 
acid import system in the liver, NTCP; is regulated by glucocorticoid is interesting to speculate 
that this mechanism controls the efficiency of the enterohepatic circulation of bile acids. 
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Regulation of bile acid uptake in the intestine: 
Jung D, Fried M, Kullak-Ublick GA: Human Apical Sodium-Dependent Bile Salt Transporter 
Gene is Regulated by the Peroxisome Proliferator-activated Receptor α. J Biol Chem. 2002 
Aug 23;277(34):30559-66. 
The major intestinal bile salt uptake system is the apical sodium-dependent bile salt transporter 
(ASBT), also called the ileal bile acid transporter. ASBT is chiefly responsible for absorption of 
bile acids into ileal enterocytes. Mutations in ASBT gene can cause primary bile acid 
malabsorption, an intestinal disorder characterized by congenital diarrhea, and reduced plasma 
cholesterol levels. Many inflammatory bowel disease (IBD) patients exhibit reduced ASBT 
expression. 
This paper showed the characterization of the promoter region of the human ASBT gene and the 
identification of a binding site for the peroxisome proliferator-activated receptor α.(PPARα). In 
vitro experiments demonstrated that cells treated with a ligand for PPARα had an increased 
expression of ASBT. In addition the binding site of PPARα was characterized by molecular 
methods including reporter and mobility shift assays. 
PPARα, has been established as a regulator of fatty acid catabolism, hepatic bile salt synthesis, 
and inflammation control. These results introduce PPARα as a novel signalling mechanism in the 
coordinate regulation of bile salt biosynthetic and transport pathways. Regulation of the chief 
human intestinal bile salt uptake system by PPARα has major implications for the interplay 
between bile salt homeostasis, lipid metabolism, and inflammation control and can be considered 
in the development of treatment strategies for lipid and inflammatory disorders associated with 
alterations in ASBT function and expression. 
The same paper reported also the regulation of ASBT by the hepatoctye nuclear factor 1α 
(HNF1α). ASBT activation by HNF1α has a potential clinical implication as it concerns the 
reduction of ASBT expression during intestinal inflammation. The importance of HNF1α for bile 
acid transporter will be discussed in the next chapter.  
 
The role of HNF1α in the regulation of bile acid transport systems 
Jung D, Hagenbuch B, Gresh L, Pontoglio M, Meier PJ, Kullak-Ublick GA: Characterization 
of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP 
genes by hepatocyte nuclear factor 1α. J Biol Chem 2001 Oct 5;276(40):37206-14 
The organic anion transporter C (OATP-C) is expressed exclusively in hepatocytes and 
represents the chief natrium-independent bile salt uptake system of human liver. Reduced 
expression of OATP-C has been observed in the chronic cholestatic liver disease primary 
sclerosing cholangitis. Mechanism regulating OATP-C expression were unknown and 
investigated.  
The paper showed the initial characterization of the promoter region of the human OATP-C gene 
and the identification of a binding site for the hepatocyte nuclear factor 1α (HNF1α). The 
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identified binding site was characterized and it was shown, that HNF1α was not only one of the 
effectors of liver-specific OATP-C expression but also critical for basal expression, as mutation of 
the HNF1α site abolished OATP-C expression. 
HNF1α belongs to the group of transcriptions factors predominately expressed in the liver and 
importance of HNF1α in directing liver-specific gene expression has become evident from the 
observation that numerous liver-specific genes possess HNF1 binding sites. Several lines of 
evidence pointed toward a role for HNF1α as a “master regulator” of hepatic organic anion 
transport proteins and this paper also showed that not only OATP-C but also OATP-8, both of 
which belong to the “liver-specific” OATP subfamily, are regulated by HNF1α. OATP8 is a 
multispefic uptake system for organic anions, xenobiotics, and peptides expressed at the 
basolateral (sinusoidal) membrane of human hepatocytes. Interestingly, OATP8 gene expression 
was shown to be regulated by bile acids via FXR and the induction of OATP8 could serve to 
maintain hepatic extraction of xenobiotics and peptides in conditions of increased intracellular bile 
acids. Of note, this was demonstrated by: “Jung D, Podvinec M, Meyer UA, Mangelsdorf DJ, 
Meier PJ, Kullak-Ublick GA: Human organic anion transporting polypeptide OATP8 (SLC21A8) 
promoter is transactivated by the farnesoid X receptor/bile acid receptor. Gastroenterology 2002”, 
and is referred as high scientific impact publication in this habilitation.  
Next to organic anion transporter bile acid transport systems have been shown to be regulated by 
HNF1α as discussed before for NTCP and ASBT. In view of HNF1α regulating the three most 
important bile acid uptakes systems in the liver and the intestine, it appears to be essential for 
bile salt transport. Of note, the role for HNF1α as global regulator was shown in a later 
publication: “Jung D, Kullak-Ublick GA.: Hepatocyte Nuclear Factor 1α: A Key Mediator of the 
Effect of Bile Acids on Gene Expression. Hepatology. 2003 Mar;37(3):622-631”, referred as 
publication with high scientific impact in this habilitation.  
 
Summary  
This ‘habilitationsschrift’ gives important new insights of the role of bile acids in the body. 
The discovery of bile acids pleiotropic actions, and daily reports addressing new roles in 
various physiological conditions, set this moment as one of the most thrilling in the 
history of the bile acids field. Bile acids and bile-acid activated FXR regulate a gene 
expression network of bile acid, cholesterol, triglyceride and glucose metabolism. In 
addition they are involved in intestinal and hepatic fitness and the response to 
inflammatory and xeniobotic insults. Thus, there is an enormous therapeutic potential 
and the future will show whether therapies can be launched from bench to bedside. 
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